Back

Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis

19 May 2025 (11:00 - 12:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (3) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Christy Rohani-Montez

Medscape Education Global, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort
Mr P. Kopp (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Usefulness of implantable loop recorders in patients with hypertrophic cardiomyopathy
Doctor M. Figueiredo (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor H. Takacs (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Phenotypic expression and prognostic determinants in TPM1-associated hypertrophic cardiomyopathy: insights from a tertiary center cohort
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Interactive case-based education significantly improves competence in diagnosing transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
thumbnail
Congress Presentation
Differentiating clinical trial endpoints in transthyretin cardiac amyloidosis is significantly improved with continuing medical education

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources